Intravenous immune globulin in the management of severe Rh D hemolytic disease.
Although intrauterine fetal transfusion has improved dramatically perinatal outcome in Rh D alloimmunization, in some cases the fetus is affected before transfusion is possible. Immune globulin (IVIG) administration is being increasingly used to successfully treat a variety of immune-mediated diseases, such as pregnancies affected by platelet alloimmunization. Although only a limited number of pregnancies have been reported, favorable outcomes with IVIG treatment of severe Rh disease have been described. We present a case report, review the published experience with IVIG treatment in severe, early-onset anti-D sensitization, and propose that IVIG may have an adjunctive role in the treatment of severe Rh isoimmunization.
Porter
T F
TF
Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City 84132, USA.
Silver
R M
RM
Jackson
G M
GM
Branch
D W
DW
Scott
J R
JR
D000328:Adult; D000906:Antibodies / Q000097:blood; D004899:Erythroblastosis, Fetal / Q000628:therapy*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007231:Infant, Newborn; D011247:Pregnancy; D012203:Rh Isoimmunization / Q000628:therapy*; D012204:Rh-Hr Blood-Group System / Q000276:immunology
D000906:Antibodies; D016756:Immunoglobulins, Intravenous; D012204:Rh-Hr Blood-Group System; C026410:Rho(D) antigen